At 6.5% CAGR, Middle East & Africa Osteoarthritis Therapy Market is Projected to be Worth US$ 762.98 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa osteoarthritis therapy market was valued at US$ 460.00 million in 2022 and is expected to reach US$ 762.98 million by 2030, registering a CAGR of 6.5% from 2022 to 2030. More effective treatment options and innovative therapy options reducing dependency on medications are among the critical factors attributed to drive the Middle East & Africa osteoarthritis therapy market growth.

Currently, there is no cure for OA. A group of clinical research scientists, through clinical trials, reveal that they are developing innovative treatment target options that can stop the progression of OA. For example, in November 2021, LG Chem company announced the initiation of a clinical trial for next-generation new drugs to treat arthritis.  Additionally, in October 2021, Pacira BioSciences, Inc. announced the acquisition of Flexion Therapeutics to treat non-opioid pain management "ZILRETTA". The drug approved in 2017 is the first and only approved treatment for OA knee pain utilizing extended-release microsphere technology. In September 2023, Sorrento Therapeutics, Inc. announced positive Phase 2 top-line clinical trial results for the "Resiniferatoxin (RTX) program". The Phase 2 trial is a multi-center, double-blind, placebo, and active-controlled study assessing the efficacy and safety of several dose groups of RTX to manage pain in patients with moderate-to-severe OAK. Also, Sorrento decided to include an active approved competitor drug, "Zilretta," in the current clinical trial protocol.

On the contrary, the product recall hampers the growth of Middle East & Africa osteoarthritis therapy market.

Based on therapy type, the Middle East & Africa osteoarthritis therapy market is segmented into transcutaneous electrical nerve stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma (PRP) therapy & stromal vascular fraction, prolotherapy, and others. The physical therapy segment held 42.7% market share in 2022, amassing US$ 196.57 million. It is projected to garner US$ 334.10 million by 2030 to register 6.9% CAGR during 2022-2030.

In terms of disease indications, the Middle East & Africa osteoarthritis therapy market is segmented into knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, hand osteoarthritis, and others. The knee osteoarthritis segment held 54.0% share of Middle East & Africa osteoarthritis therapy market in 2022, amassing US$ 248.34 million. It is anticipated to garner US$ 419.63 million by 2030 to expand at 6.8% CAGR during 2022-2030.

Based on end user, the Middle East & Africa osteoarthritis therapy market is categorized into hospitals and clinics, specialty clinics, ambulatory surgical center, homecare, and others. The homecare segment held 33.5% share of Middle East & Africa osteoarthritis therapy market in 2022, amassing US$ 153.89 million. It is predicted to garner US$ 248.88 million by 2030 to expand at 6.2% CAGR between 2022 and 2030.

Based on country, the Middle East & Africa osteoarthritis therapy market is categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that South Africa captured 36.9% share of Middle East & Africa osteoarthritis therapy market in 2022. It was assessed at US$ 169.93 million in 2022 and is likely to hit US$ 285.02 million by 2030, registering a CAGR of 6.7% during 2022-2030.

Key players operating in the Middle East & Africa osteoarthritis therapy market are Estar Technologies Ltd, Zimmer Biomet Holdings Inc, DePuy Synthes Inc, Bioventus Inc, Omron Healthcare Inc, and Medi GmbH & Co KG, among others.

• In March-2022, VQ OrthoCare introduced the OActive Align Osteoarthritis Knee Brace. The OActive Align offers clinicians an easy solution for custom-fitting and aligning the brace to produce exceptional patient outcomes. The brace employs a unique combination of features that precisely fit the anatomy, align the brace hinge axis, and secure it in its most effective position for corrective pain relief.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com